The clinical effect of virtual reality- and inhibitory learning-based dynamic exposure therapy for panic disorder and agoraphobia

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0008289

Enrollment

Registered

2023-03-16

Start date

2023-03-06

Completion date

Unknown

Last updated

2023-04-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Behavioral : 1) Patient groups (total n = 60) - A four-session (weekly) exposure training for the following two groups: - Plain exposure therapy (n = 30): Although personally tailored exposure con

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: a) Aged 18 to 64 b) Patients: Diagnosed with Panic Disorder (E) or Agoraphobia (F) by the Mini-International Neuropsychiatric Interview (MINI). / Healthy: No current psychiatric disorders including panic disorder and agoraphobia c) Enough verbal and cognitive abilities to understand the consent form, answer the questionnaire, and operate VR devices/programs d) Received detailed explanation regarding the study, adequately understood them, and volunteerly decided and give consent to participate in the study

Exclusion criteria

Exclusion criteria: a) Patient: Moderate or more suicide tendency (C), current manic (not hypomanic) episode (D), current/lifetime psychotic disorders (L), or psychopathy (P) is diagnosed in the MINI. Or past diagnosis records of psychotic disorders or severe bipolar disorder. / Healthy: Current significant psychiatric disorders b) Suicide attempts within recent six months c) Current/past epilepsy or photosensitive syndrome d) Visual impairment (except for correctable ametropia or dyschromatopsia) e) auditory disorders or moderate or severe hearing loss f) Impairment of voluntary movements that may hinder the operation of VR programs g) Serious clinical problems in the cardiovascular system, digestive system, respiratory system, endocrine system, or central nervous system that make it difficult to participate in the study H) Pregnant or lactating women I) Those who are judged unsuitable for research due to other reasons by principal investigators or those in charge

Design outcomes

Primary

Measure	Time frame
Panic Disorder Severity Scale;Mobility Inventory for Agoraphobia	—

Secondary

Measure	Time frame
The Center for Epidemiologic Studies Depression Scale;Anxiety Sensitivity Index;State-Trait Anxiety Inventory;Visual Analogue Scale for Anxiety;3D Presence/Fatigue;Electroencephalography;Functional Near-Infrared Spectroscopy;Heart Rate Variability;Skin conductance	—

Countries

Korea, Republic of

Contacts

Public ContactHan Jung

Hallym University Medical Center- Chuncheon

jhw2@naver.com+82-33-240-5739

Outcome results